A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer.
Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist. All the patients had been previously operated on and all had received at least one regimen of chemotherapy. Duration of decapeptyl administration was between 1 month and 28 weeks. There were no complete or partial responses. Eight patients (57%) had disease stabilization with a median progression-free interval of 14 weeks (range 4-28 weeks). All other patients developed a clear progressive cancer after the first injection of LHRH agonist. Three of these patients are still alive and receiving other forms of chemotherapy (median follow-up after the end of LHRH treatment was 11.5 months). The regimen was well tolerated with only mild toxicity observed (hot flushes in 2 patients). Although D-Trp-6-LHRH (Decapeptyl) was well tolerated, it had insignificant activity in treating patients with epithelial cancer that was resistant or relapsed after first-line platinum-based chemotherapy.
Ron
I G
IG
Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.
Wigler
N
N
Merimsky
O
O
Inbar
M J
MJ
Chaitchik
S
S
D000368:Aged; D002277:Carcinoma / Q000188:drug therapy; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy; D017211:Treatment Failure; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000627:therapeutic use*
D017329:Triptorelin Pamoate